Skip to main content
Erschienen in: Osteoporosis International 1/2016

01.01.2016 | Original Article

Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study

verfasst von: W. Brozek, B. Reichardt, J. Zwerina, H. P. Dimai, K. Klaushofer, E. Zwettler

Erschienen in: Osteoporosis International | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Summary

We analyzed the association of bisphosphonate therapy with mortality and hip refracture incidence among osteoporosis-related hip fracture patients in Austria. Mortality was lower in primarily female bisphosphonate users, while hip refracture incidence was generally elevated relative to controls, indicating beneficial effects of bisphosphonates other than on bone.

Introduction

The purpose of this study was to analyze mortality and hip refracture risk in osteoporotic hip fracture patients with and without antiosteoporotic medication.

Methods

We retrospectively analyzed data on 31,668 Austrian patients ≥50 years with a hip fracture between July 2008 and December 2010 for antiosteoporotic drug treatment with respect to outcome parameters all-cause mortality, hip refracture incidence, and hip refracture-free days. Outcomes when bisphosphonate (BP) treatment was begun before or after fracture were compared with an age- and sex-matched hip fracture control without antiosteoporotic medication.

Results

27.69 % of patients (33.01 % of women, 13.13 % of men) were prescribed antiosteoporotic medication, primarily BPs. Females having initiated BP treatment before first fracture had lower odds for mortality 1 and 3 year(s) post-fracture, whereas hip refracture incidence under pre-fracture BP initiation was generally higher. Treatment that was started after fracture, however, entailed significantly lower mortality hazards for both genders (HR 0.43, 95 %CI 0.36–0.52, p < 0.0001 after 1 year) but significantly higher hip refracture incidence except for patients aged 50–69 years and more hip refracture free days for females. Hip refractures overall amounted to 29.22/1000 patient years differing significantly between women and men (31.03 vs. 23.89, respectively, p < 0.0001), and longer hip refracture free survival was observed for women than for men (499 vs. 466 median days, respectively, p < 0.0001).

Conclusions

Although BP use is associated with reduced mortality after hip fracture, notably among women, hip refracture incidences are likewise elevated, which is most likely accounted for by a high probability of BP prescription to more comorbid patients suffering from more severe osteoporosis. Concomitantly, through possible effects other than on bone, BPs might be able to curtail mortality. Male hip fracture patients’ low treatment frequency in particular reflects underdiagnosis and undertreatment of osteoporosis in Austria.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Zurück zum Zitat Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39:1157–1163PubMedCrossRef Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39:1157–1163PubMedCrossRef
3.
Zurück zum Zitat Armstrong AL, Wallace WA (1994) The epidemiology of hip fractures and methods of prevention. Acta Orthop Belg 60(S1):85–101PubMed Armstrong AL, Wallace WA (1994) The epidemiology of hip fractures and methods of prevention. Acta Orthop Belg 60(S1):85–101PubMed
4.
Zurück zum Zitat McClung MR (2003) Pathogenesis of osteoporotic hip fractures. Clin Cornerstone 5(S2):S22–S29CrossRef McClung MR (2003) Pathogenesis of osteoporotic hip fractures. Clin Cornerstone 5(S2):S22–S29CrossRef
5.
Zurück zum Zitat Bischoff-Ferrari H (2011) The role of falls in fracture prediction. Curr Osteoporos Rep 9:116–121PubMedCrossRef Bischoff-Ferrari H (2011) The role of falls in fracture prediction. Curr Osteoporos Rep 9:116–121PubMedCrossRef
6.
Zurück zum Zitat Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423PubMedCrossRef Boonen S, Lips P, Bouillon R, Bischoff-Ferrari HA, Vanderschueren D, Haentjens P (2007) Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 92:1415–1423PubMedCrossRef
7.
Zurück zum Zitat Abrahamsen B, Masud T, Avenell A, Anderson F, Meyer HE, Cooper C et al (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340:b5463CrossRef Abrahamsen B, Masud T, Avenell A, Anderson F, Meyer HE, Cooper C et al (2010) Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 340:b5463CrossRef
8.
Zurück zum Zitat Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281–300PubMedCrossRef Rizzoli R (2011) Bisphosphonates for post-menopausal osteoporosis: are they all the same? QJM 104:281–300PubMedCrossRef
9.
Zurück zum Zitat Reginster J-Y (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65–78PubMedCrossRef Reginster J-Y (2011) Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 71:65–78PubMedCrossRef
10.
Zurück zum Zitat Alves SM, Economou T, Oliveira C, Ribeiro AI, Neves N, Goméz-Barrena E et al (2013) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone 53:430–436PubMedCrossRef Alves SM, Economou T, Oliveira C, Ribeiro AI, Neves N, Goméz-Barrena E et al (2013) Osteoporotic hip fractures: bisphosphonates sales and observed turning point in trend. A population-based retrospective study. Bone 53:430–436PubMedCrossRef
11.
Zurück zum Zitat Fisher AA, O’Brien ED, Davis MW (2009) Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 45:246–253PubMedCrossRef Fisher AA, O’Brien ED, Davis MW (2009) Trends in hip fracture epidemiology in Australia: possible impact of bisphosphonates and hormone replacement therapy. Bone 45:246–253PubMedCrossRef
12.
13.
Zurück zum Zitat Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E et al (2011) Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int 22:685–692PubMedCrossRef Dimai HP, Svedbom A, Fahrleitner-Pammer A, Pieber T, Resch H, Zwettler E et al (2011) Epidemiology of hip fractures in Austria: evidence for a change in the secular trend. Osteoporos Int 22:685–692PubMedCrossRef
14.
Zurück zum Zitat Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765PubMedCrossRef
15.
Zurück zum Zitat Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256PubMedCrossRef Eriksen EF, Keaveny TM, Gallagher ER, Krege JH (2014) Literature review: the effects of teriparatide therapy at the hip in patients with osteoporosis. Bone 67:246–256PubMedCrossRef
16.
Zurück zum Zitat Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2014) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014CrossRef Center JR, Bliuc D, Nguyen ND, Nguyen TV, Eisman JA (2014) Osteoporosis medication and reduced mortality risk in elderly women and men. J Clin Endocrinol Metab 96:1006–1014CrossRef
17.
Zurück zum Zitat Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG et al (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551–2556PubMedCrossRef Sambrook PN, Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG et al (2011) Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study. Osteoporos Int 22:2551–2556PubMedCrossRef
18.
Zurück zum Zitat Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRef
19.
Zurück zum Zitat Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ et al (2010) Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J Bone Miner Res 25:866–872PubMed Cameron ID, Chen JS, March LM, Simpson JM, Cumming RG, Seibel MJ et al (2010) Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study. J Bone Miner Res 25:866–872PubMed
20.
Zurück zum Zitat Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG et al (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991PubMedCrossRef Beaupre LA, Morrish DW, Hanley DA, Maksymowych WP, Bell NR, Juby AG et al (2011) Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 22:983–991PubMedCrossRef
21.
Zurück zum Zitat Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int 24:245–252PubMedCrossRef Bondo L, Eiken P, Abrahamsen B (2013) Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients—a nationwide register-based open cohort study. Osteoporos Int 24:245–252PubMedCrossRef
22.
Zurück zum Zitat Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181PubMedCrossRef Bolland MJ, Grey AB, Gamble GD, Reid IR (2010) Effect of osteoporosis treatment on mortality: a meta-analysis. J Clin Endocrinol Metab 95:1174–1181PubMedCrossRef
23.
Zurück zum Zitat Nieves JW, Cosman F (2010) Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 8:34–39PubMedCrossRef Nieves JW, Cosman F (2010) Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates. Curr Osteoporos Rep 8:34–39PubMedCrossRef
24.
Zurück zum Zitat Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRef Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRef
25.
Zurück zum Zitat Lee Y-K, Ha Y-C, Park C, Yoo JJ, Shin CS, Koo K-H (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24:707–711PubMedCrossRef Lee Y-K, Ha Y-C, Park C, Yoo JJ, Shin CS, Koo K-H (2013) Bisphosphonate use and increased incidence of subtrochanteric fracture in South Korea: results from the National Claim Registry. Osteoporos Int 24:707–711PubMedCrossRef
26.
Zurück zum Zitat Lee Y-K, Ha Y-C, Choi HJ, Jang S, Park C, Lim Y-T et al (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int 24:2887–2892PubMedCrossRef Lee Y-K, Ha Y-C, Choi HJ, Jang S, Park C, Lim Y-T et al (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int 24:2887–2892PubMedCrossRef
27.
Zurück zum Zitat Shen S-H, Huang K-C, Tsai Y-H, Yang T-Y, Lee MS, Ueng SWN et al (2014) Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc 15:725–731PubMedCrossRef Shen S-H, Huang K-C, Tsai Y-H, Yang T-Y, Lee MS, Ueng SWN et al (2014) Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc 15:725–731PubMedCrossRef
28.
Zurück zum Zitat Brozek W, Reichardt B, Kimberger O, Zwerina J, Dimai HP, Kritsch D et al (2014) Mortality after hip fracture in Austria 2008–2011. Calcif Tissue Int 95:257–266PubMedCrossRef Brozek W, Reichardt B, Kimberger O, Zwerina J, Dimai HP, Kritsch D et al (2014) Mortality after hip fracture in Austria 2008–2011. Calcif Tissue Int 95:257–266PubMedCrossRef
29.
Zurück zum Zitat Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J (2015) The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 7:65–76PubMedPubMedCentral Willson T, Nelson SD, Newbold J, Nelson RE, LaFleur J (2015) The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol 7:65–76PubMedPubMedCentral
30.
Zurück zum Zitat Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977–2001. J Bone Miner Res 24:1299–1307PubMedCrossRef Ryg J, Rejnmark L, Overgaard S, Brixen K, Vestergaard P (2009) Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977–2001. J Bone Miner Res 24:1299–1307PubMedCrossRef
31.
Zurück zum Zitat Lawrence TM, Wenn R, Boulton CT, Moran CG (2010) Age-specific incidence of first and second fractures of the hip. J Bone Joint Surg (Br) 92:258–261CrossRef Lawrence TM, Wenn R, Boulton CT, Moran CG (2010) Age-specific incidence of first and second fractures of the hip. J Bone Joint Surg (Br) 92:258–261CrossRef
32.
Zurück zum Zitat Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353–1357PubMedCrossRef Nymark T, Lauritsen JM, Ovesen O, Röck ND, Jeune B (2006) Short time-frame from first to second hip fracture in the Funen County Hip Fracture Study. Osteoporos Int 17:1353–1357PubMedCrossRef
33.
Zurück zum Zitat Lönnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I, Sulkava R (2007) Incidence of second hip fractures. A population-based study. Osteoporos Int 18:1279–1285PubMedCrossRef Lönnroos E, Kautiainen H, Karppi P, Hartikainen S, Kiviranta I, Sulkava R (2007) Incidence of second hip fractures. A population-based study. Osteoporos Int 18:1279–1285PubMedCrossRef
34.
Zurück zum Zitat Ishtiaq S, Fogelman I, Hampson G (2015) Treatment of post-menopausal osteoporosis: beyond bisphosphonates. J Endocrinol Investig 38:13–29CrossRef Ishtiaq S, Fogelman I, Hampson G (2015) Treatment of post-menopausal osteoporosis: beyond bisphosphonates. J Endocrinol Investig 38:13–29CrossRef
35.
Zurück zum Zitat Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMedCrossRef Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P et al (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91–97PubMedCrossRef
36.
Zurück zum Zitat Le Goff B, Berthelot J-M, Maugars Y, Romas E (2010) Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 16:3045–3052PubMedCrossRef Le Goff B, Berthelot J-M, Maugars Y, Romas E (2010) Alternative use of bisphosphonate therapy for rheumatic disease. Curr Pharm Des 16:3045–3052PubMedCrossRef
37.
Zurück zum Zitat Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S et al (2015) Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer Treat Rev 41:61–68PubMedCrossRef Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S et al (2015) Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. Cancer Treat Rev 41:61–68PubMedCrossRef
38.
Zurück zum Zitat Santos LL, Cavalcanti TB, Bandeira FA (2012) Vascular effects of bisphosphonates—a systematic review. Clin Med Insights Endocrinol Diabetes 5:47–54PubMedPubMedCentralCrossRef Santos LL, Cavalcanti TB, Bandeira FA (2012) Vascular effects of bisphosphonates—a systematic review. Clin Med Insights Endocrinol Diabetes 5:47–54PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One 10:e0122646PubMedPubMedCentralCrossRef Kim DH, Rogers JR, Fulchino LA, Kim CA, Solomon DH, Kim SC (2015) Bisphosphonates and risk of cardiovascular events: a meta-analysis. PLoS One 10:e0122646PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Thaler R, Spitzer S, Karlic H, Berger C, Klaushofer K, Varga F (2013) Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol 85:173–185PubMedPubMedCentralCrossRef Thaler R, Spitzer S, Karlic H, Berger C, Klaushofer K, Varga F (2013) Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. Biochem Pharmacol 85:173–185PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104:1059–1067PubMedCrossRef Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104:1059–1067PubMedCrossRef
42.
Zurück zum Zitat Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef
43.
Zurück zum Zitat Misof BM, Patsch JM, Roschger P, Muschitz C, Gamsjaeger S, Paschalis EP et al (2014) Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res 29:440–449PubMedCrossRef Misof BM, Patsch JM, Roschger P, Muschitz C, Gamsjaeger S, Paschalis EP et al (2014) Intravenous treatment with ibandronate normalizes bone matrix mineralization and reduces cortical porosity after two years in male osteoporosis: a paired biopsy study. J Bone Miner Res 29:440–449PubMedCrossRef
44.
Zurück zum Zitat Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581PubMedCrossRef Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581PubMedCrossRef
45.
Zurück zum Zitat Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26:546–550PubMedPubMedCentralCrossRef Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26:546–550PubMedPubMedCentralCrossRef
Metadaten
Titel
Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study
verfasst von
W. Brozek
B. Reichardt
J. Zwerina
H. P. Dimai
K. Klaushofer
E. Zwettler
Publikationsdatum
01.01.2016
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 1/2016
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-015-3415-4

Weitere Artikel der Ausgabe 1/2016

Osteoporosis International 1/2016 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.